Literature DB >> 1353613

Kappa opioid agonists inhibit transmitter release from guinea pig hippocampal mossy fiber synaptosomes.

R L Gannon1, D M Terrian.   

Abstract

Opioid agonists specific for the mu, delta, and kappa opioid receptor subtypes were tested for their ability to modulate potassium-evoked release of L-glutamate and dynorphin B-like immunoreactivity from guinea pig hippocampal mossy fiber synaptosomes. The kappa opioid agonists U-62,066E and (-) ethylketocyclazocine, but not the mu agonist [D-Ala2,N-MePhe4,Gly5-ol]-enkephalin (DAGO) nor the delta agonist [D-Pen2,5]enkephalin (DPDE), inhibited the potassium-evoked release of L-glutamate and dynorphin B-like immunoreactivity. U-62,066E, but not DAGO or DPDE, also inhibited the potassium-evoked rise in mossy fiber synaptosomal cytosolic Ca2+ levels, indicating a possible mechanism for kappa agonist inhibition of transmitter release. DAGO and DPDE were found to be without any effect on cytosolic Ca2+ levels or transmitter release in this preparation. The U-62,066E inhibition of the potassium-evoked rise in synaptosomal cytosolic Ca2+ levels was partially attenuated by the opioid antagonist quadazocine and insensitive to the delta-opioid specific antagonist ICI 174,864 and the mu opioid-preferring antagonists naloxone and naltrexone. Quadazocine also reversed U-62,066E inhibition of the potassium-evoked release of L-glutamate, but not dynorphin B-like immunoreactivity. These results suggest that kappa opioid agonists inhibit transmitter release from mossy fiber terminals through both kappa opioid and non-kappa opioid receptor mediated mechanisms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353613     DOI: 10.1007/bf00969007

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  42 in total

1.  Glutamate and dynorphin release from a subcellular fraction enriched in hippocampal mossy fiber synaptosomes.

Authors:  D M Terrian; D Johnston; B J Claiborne; R Ansah-Yiadom; W J Strittmatter; M A Rea
Journal:  Brain Res Bull       Date:  1988-09       Impact factor: 4.077

Review 2.  Methods used for the study of opioid receptors.

Authors:  F M Leslie
Journal:  Pharmacol Rev       Date:  1987-09       Impact factor: 25.468

3.  Dynorphin A selectively reduces a large transient (N-type) calcium current of mouse dorsal root ganglion neurons in cell culture.

Authors:  R A Gross; R L Macdonald
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

4.  Fluorometric determination of aspartate, glutamate, and gamma-aminobutyrate in nerve tissue using enzymic methods.

Authors:  L T Graham; M H Aprison
Journal:  Anal Biochem       Date:  1966-06       Impact factor: 3.365

5.  The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties.

Authors:  J Magnan; S J Paterson; A Tavani; H W Kosterlitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-06       Impact factor: 3.000

6.  Multiple opioid receptor profile in vitro and activity in vivo of the potent opioid antagonist Win 44,441-3.

Authors:  S J Ward; A K Pierson; W F Michne
Journal:  Life Sci       Date:  1983       Impact factor: 5.037

7.  Possible mechanism involved in the inhibitory action of U-50, 488H, an opioid kappa agonist, on guinea pig hippocampal CA3 pyramidal neurons in vitro.

Authors:  T Iwama; K Ishihara; H Takagi; M Satoh
Journal:  J Pharmacobiodyn       Date:  1987-10

Review 8.  Seizures, neuropeptide regulation, and mRNA expression in the hippocampus.

Authors:  C Gall; J Lauterborn; P Isackson; J White
Journal:  Prog Brain Res       Date:  1990       Impact factor: 2.453

9.  Characterization of the presynaptic calcium channels involved in glutamate exocytosis from rat hippocampal mossy fiber synaptosomes.

Authors:  D M Terrian; R V Dorman; R L Gannon
Journal:  Neurosci Lett       Date:  1990-11-13       Impact factor: 3.046

10.  Seizures induce dramatic and distinctly different changes in enkephalin, dynorphin, and CCK immunoreactivities in mouse hippocampal mossy fibers.

Authors:  C Gall
Journal:  J Neurosci       Date:  1988-06       Impact factor: 6.167

View more
  5 in total

Review 1.  Pathobiology of dynorphins in trauma and disease.

Authors:  Kurt F Hauser; Jane V Aldrich; Kevin J Anderson; Georgy Bakalkin; MacDonald J Christie; Edward D Hall; Pamela E Knapp; Stephen W Scheff; Indrapal N Singh; Bryce Vissel; Amina S Woods; Tatiana Yakovleva; Toni S Shippenberg
Journal:  Front Biosci       Date:  2005-01-01

2.  Dynorphin A (1-13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons.

Authors:  K F Hauser; J K Foldes; C S Turbek
Journal:  Exp Neurol       Date:  1999-12       Impact factor: 5.330

3.  In vitro and in vivo efficacy of a potent opioid receptor agonist, biphalin, compared to subtype-selective opioid receptor agonists for stroke treatment.

Authors:  Li Yang; Mohammad R Islam; Vardan T Karamyan; Thomas J Abbruscato
Journal:  Brain Res       Date:  2015-03-20       Impact factor: 3.252

4.  Nalfurafine, the kappa opioid agonist, inhibits icilin-induced wet-dog shakes in rats and antagonizes glutamate release in the dorsal striatum.

Authors:  Jennifer L Werkheiser; Scott M Rawls; Alan Cowan
Journal:  Neuropharmacology       Date:  2006-12-05       Impact factor: 5.250

5.  Increased locus coeruleus glutamate levels are associated with naloxone-precipitated withdrawal from butorphanol in the rat.

Authors:  Y Z Feng; T Zhang; R W Rockhold; I K Ho
Journal:  Neurochem Res       Date:  1995-06       Impact factor: 3.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.